Pipeline

Edge is working with researchers around the world to develop a rich pipeline of drugs targeting delayed complications occurring after brain hemorrhage, TBI and Brain Surgery. The products – innovative formulations of known FDA-approved drugs – provide for direct therapeutic delivery to the site of injury in the brain and will be used in the operating room or intensive care setting. The Company’s proprietary bioabsorbable formulations release drugs locally and consistently at therapeutic concentrations in the brain, with the objective of maximizing therapeutic activity and avoiding treatment-limiting systemic side effects. Edge is building a portfolio of de-risked assets by combining FDA-approved products with a proprietary bioabsorbable delivery system.

Edge’s lead products, EG-1962 (nimodipine microparticles) and EG-1964, are in front of two trends simultaneously occurring in the neurosurgical marketplace; the transition of microsurgical clipping to endovascular coiling in the aneurysmal subarachnoid hemorrhage (aSAH) treatment marketplace, more commonly known as ruptured brain aneurysms, and the aging population or graying of the world causing an increase in chronic subdural hematomas. Overall, the Company’s robust portfolio of three novel products addressing six unique indications is designed to fundamentally change how brain injuries associated with bleeding are treated.